A5058644667- Immunotherapy and Immune Responses
- Ovarian cancer diagnosis and treatment
- Cancer Mechanisms and Therapy
- Multiple Sclerosis Research Studies
- Cancer Immunotherapy and Biomarkers
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Metabolomics and Mass Spectrometry Studies
- Cancer, Lipids, and Metabolism
- SARS-CoV-2 and COVID-19 Research
- Health Systems, Economic Evaluations, Quality of Life
- Skin and Cellular Biology Research
- Amyotrophic Lateral Sclerosis Research
- Psoriasis: Treatment and Pathogenesis
- Virus-based gene therapy research
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Bacillus and Francisella bacterial research
- Systemic Sclerosis and Related Diseases
- Spondyloarthritis Studies and Treatments
- Statistical Methods in Clinical Trials
- Advanced Causal Inference Techniques
- Ultrasound and Hyperthermia Applications
- CAR-T cell therapy research
Sotio (Czechia)
2021-2023
General University Hospital in Prague
2021-2023
Charles University
2019-2023
University of Pardubice
2021-2022
Apigenex (Czechia)
2019
Pancreatic cancer has the worst prognosis among all cancers. Cancer screening of body fluids may improve survival time patients, who are often diagnosed too late at an incurable stage. Several studies report dysregulation lipid metabolism in tumor cells, suggesting that changes blood lipidome accompany growth. Here we show comprehensive mass spectrometric determination a wide range serum lipids reveals statistically significant differences between pancreatic patients and healthy controls, as...
Background Most patients with epithelial ovarian cancer (EOC) relapse despite primary debulking surgery and chemotherapy (CT). Autologous dendritic cell immunotherapy (DCVAC) can present tumor antigens to elicit a durable immune response. We hypothesized that adding parallel or sequential DCVAC CT stimulates antitumor immunity improves clinical outcomes in EOC. Based on the interim results of DCVAC/OvCa administration accommodate increased interest maintenance treatment EOC, trial was...
The successful implementation of immune checkpoint inhibitors (ICI) in the clinical management various solid tumors has raised considerable expectations for patients with epithelial ovarian carcinoma (EOC). However, EOC is poorly responsive to ICIs due immunologic features including limited tumor mutational burden (TMB) and poor lymphocytic infiltration. An autologous dendritic cell (DC)-based vaccine (DCVAC) recently been shown be safe significantly improve progression-free survival (PFS) a...
Background: Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury. There lack studies investigating the dynamics relationships between sNfL levels and radiological disease activity over long-term follow-up in multiple sclerosis (MS). Objectives: To investigate relationship among repeated measures sNfL, lesion burden accumulation, brain volume loss clinical measures. Methods: We investigated 172 patients early stages MS (McDonald 2017 criteria). Clinical exams were...
DCVAC/OvCa is an active cellular immunotherapy designed to stimulate immune response against ovarian cancer. We explored the safety and efficacy of plus carboplatin gemcitabine in platinum-sensitive cancer.In this open-label, parallel-group, phase 2 trial (ClinicalTrials.gov number NCT02107950), patients with cancer relapsing after first-line chemotherapy were randomized or alone. was administered every 3-6 weeks (10 doses). Endpoints included safety, progression-free survival (PFS; primary...
Dendritic cells (DCs) have received considerable attention as potential targets for the development of novel cancer immunotherapies. However, clinical efficacy DC-based vaccines remains suboptimal, largely reflecting local and systemic immunosuppression at baseline. An autologous vaccine (DCVAC) has recently been shown to improve progression-free survival overall in randomized trials enrolling patients with lung (SLU01, NCT02470468) or ovarian carcinoma (SOV01, NCT02107937), but not...
Pancreatic cancer has the worst prognosis among all cancers 1 . Cancer screening programs based on analysis of body fluids can improve survival time patients, who are often diagnosed too late at an incurable stage 2 Several studies have reported dysregulation lipid metabolism in tumor cells and tissues 3 , suggesting that changes blood lipidome may accompany growth progression. Analytical methods mass spectrometry (MS) using either direct infusion or chromatographic separation 4 convenient...
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Early infratentorial and focal spinal cord lesions on magnetic resonance imaging (MRI) are associated with a higher risk of long-term disability in patients multiple sclerosis (MS). The role diffuse remains less understood. purpose this study was to evaluate especially early relapsing-remitting MS their association intracranial lesion topography, global regional brain volume, volume.We investigated 58 short disease duration (< 5 years) from large academic center healthy controls matched for...
5521 Background: Most patients with EOC relapse despite PDS and CMT. Autologous DCVAC can present tumor antigens to elicit a durable immune response. We hypothesized that adding CMT stimulates antitumor immunity improves clinical outcomes. Methods: Key eligibility criteria were FIGO stage III (serous, endometrioid, or mucinous), post-PDS < 1 cm maximal residuum, no prior systemic therapy, ECOG 0-2. In part 1, randomized up 6 weeks after PDS, 1:1:1, into arm A (A; concomitant CMT), B (B;...
Supplementary Data from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors
Supplementary Figure from An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer Low Mutational Burden and Cold Tumors